Clinically, breast cancer is subdivided into three subtypes based on the immunohistochemistry (IHC) status of hormone receptors’ (HRs) estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and breast cancer.